FDA Inspection 1231238 — Imprimis NJOF, LLC
The FDA completed an inspection of Imprimis NJOF, LLC on April 3, 2024 in Ledgewood, NJ. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). Product area: Drugs.
Inspection Details
- Classification
- Official Action Indicated (OAI) (OAI)
- End Date
- April 3, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Ledgewood, NJ (United States)